SNIPR 001
Alternative Names: SNIPR-001Latest Information Update: 28 Jun 2025
At a glance
- Originator SNIPR Biome
- Class Antibacterials; Gene therapies; Urinary anti-infective agents
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Escherichia coli infections
- Preclinical Sepsis; Urinary tract infections
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Escherichia-coli-infections(Prevention) in Denmark (PO)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Escherichia-coli-infections(In volunteers) in USA (PO)
- 25 Feb 2025 SNIPR Biome initiates a phase Ib/IIa trial in Escherichia coli infections (Prevention) in USA (PO) (NCT06938867)